BRIEF-Arbutus provides additional data from the ARB-1467 phase II clinical trial in HBV patients
December 12, 2016 at 16:09 PM EST
* Arbutus Biopharma - one patient in cohort 2 discontinued treatment due to transient elevation of transaminases with normal bilirubin observed
